Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BMS CA180-097: A Phase II Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer, Previously Treated With Chemotherapy

NCT00570700 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT00570700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00570700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BMS CA180-097: A Phase II Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer, Previously Treated With Chemotherapy
Lead sponsor
University of California, Irvine
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
February 29, 2012
Enrollment
38 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the prostate, hormone-refractory prostate cancer, hormone-resistant prostate cancer, prostate cancer, recurrent prostate cancer